Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the route of administration for Basaglar® (insulin glargine)?

Basaglar is administered as a subcutaneous injection.

US_cFAQ_BIV022_ROUTE_OF_ADMINISTRATION
US_cFAQ_BIV022_ROUTE_OF_ADMINISTRATION
en-US

Route of Administration

Administer Basaglar® (insulin glargine) 100 units/mL subcutaneously into the abdominal area, thigh, or deltoid.1

Administration Instructions

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.1

Do not dilute or mix Basaglar with any other insulin or solution.1

Do not administer Basaglar intravenously or via an insulin pump.1

Route of Administration Versus Duration of Action

In patients with type 1 diabetes, after subcutaneous injection of 0.3 units/kg of another insulin glargine 100 units/mL product, the duration of action after abdominal, deltoid, or thigh administration was similar.1

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 19, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical